Moreover, the findings that higher levels of GlycACE2 and reduced ACE2/Ang 1–7, 1–9/MasR axis with a parallel increase of myocardial fibrosis were observed only in diabetic patients, as well as the improvement of anti-remodeling effects of RAS inhibition in diabetic patients with HbA1c levels < 7% suggest a pivotal role of glycemic control in the efficacy of both ACE-I and ARB therapy. This evidence concerns the gene ACE2 and Myocardial fibrosis.